AUTHOREA
Log in Sign Up Browse Preprints

loading page

COVID-19 in an adolescent with aplastic anemia undergoing immunosuppressive therapy: a case report and details of antibody testing for SARS-CoV-2
  • +7
  • Shota Kato,
  • Yoshiko Nakano,
  • Yuki Nakano,
  • Koh Okamoto,
  • Nao Takasugi,
  • Moe Hidaka,
  • Masahiro Sekiguchi,
  • Mitsuteru Hiwatari,
  • Makoto Kurano,
  • Motohiro Kato
Shota Kato
The University of Tokyo
Author Profile
Yoshiko Nakano
The University of Tokyo
Author Profile
Yuki Nakano
The University of Tokyo
Author Profile
Koh Okamoto
The University of Tokyo
Author Profile
Nao Takasugi
The University of Tokyo
Author Profile
Moe Hidaka
The University of Tokyo
Author Profile
Masahiro Sekiguchi
The University of Tokyo
Author Profile
Mitsuteru Hiwatari
The University of Tokyo
Author Profile
Makoto Kurano
The University of Tokyo
Author Profile
Motohiro Kato
The University of Tokyo

Corresponding Author:katom-tky@g.ecc.u-tokyo.ac.jp

Author Profile

Abstract

The clinical course of COVID-19 in pediatric patients with aplastic anemia (AA) have not been thoroughly investigated. We report a case of COVID-19 in a 15-year-old male with AA treated via immunosuppressive therapy. The patient initially presented with a fever and mild sore throat. He continued cyclosporine treatment, and his symptoms improved with a single dose of hydrocortisone. Antibody testing showed increased anti-S1 and anti-RBD IgA levels, followed by elevation of anti-S1 and anti-N IgM/IgG levels. Our results suggest that AA is not necessarily associated with a higher risk of severe COVID-19.